Last reviewed · How we verify
somatropin - GH treated cohort (somatropin-gh-treated-cohort)
At a glance
| Generic name | somatropin-gh-treated-cohort |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | FDA-approved |
| Annual revenue | 446 |
Approved indications
Common side effects
Key clinical trials
- Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency (PHASE2)
- Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS (PHASE3)
- Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- somatropin - GH treated cohort CI brief — competitive landscape report
- somatropin - GH treated cohort updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI